THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 13, 2004--Amgen Inc.
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced the appointment of Rolf Hoffmann to the position of senior
vice president, Amgen Europe. Hoffmann will be responsible for setting
Amgen´s commercial strategy in Europe and continuing to grow Amgen´s
presence in Europe.
"Rolf brings to Amgen a wealth of international management
experience gained over nearly 20 years in the pharmaceutical
industry," said George Morrow, Amgen´s executive vice president,
Global Commercial Operations. "I am confident he will prove a strong
leader who can build upon our track record of success in Europe."
Hoffmann joins Amgen from Eli Lilly & Company where he worked for
17 years in a variety of sales and marketing and executive management
positions. His sales and marketing positions at Lilly included product
manager for Prozac(R) and national sales manager for Lilly´s Central
Nervous System franchise. Most recently, Hoffmann held positions at
Lilly as area director, Latin America, president, InterAmerica, and
general manager, Germany.
Hoffmann received a master´s degree in English from the University
of Koeln in Koeln, Germany, a master´s degree in Kinesiology from the
Deutsche Sporthoschschule, also in Koeln, Germany, and a master´s
degree in Business Administration from the University of North
Carolina´s Kenan-Flagler Business School.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (U.S. media)
Sabeena Ahmad, 011-41-41-3692-530 (European media)
Laura Biswas, 805-447-1060 (investors)